MSF letter to ViiV asking the company to withdraw problematic purchasing conditions for HIV prevention drug CAB-LA

MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

Pro-access recommendations should serve as a blueprint for the EU to ensure equitable global access to medical tools in a future pandemic

Gavi must do more to vaccinate children up to age five, and waive co-financing requirements of countries with fragile health systems or in humanitarian crisis

MSF statement at the 5th Intergovernmental Negotiating Body (INB) on WHO Pandemic Accord

MSF welcomes WHA resolution on strengthening diagnostic testing in low- and middle-income countries

A discussion during WHA 2023 on pandemic preparedness and response, with access to Ebola treatments as an example

MSF activities at the 76th session of the World Health Assembly (WHA), 21-30 May 2023.

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.